Pasternak, Richard C.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),1 published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,2 followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs "usual care" in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.2 Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . .
|Export/Citation:||EndNote | BibTeX | Dublin Core | ASCII (Chicago style) | HTML Citation | OpenURL | Reference Manager|
|Social Networking:|| |
|Additional Information:||This article is available at the publisher’s Web site. Access to the full text is subject to the publisher’s access restrictions.|
|Uncontrolled Keywords:||lipid-lowering trial; hypertension study; pravastatin|
|Subjects:||Health > Pharmacotherapy|
Health > Public Health > Chronic Illness & Diseases > Hypertension
Research > studies
|Depositing User:||Users 141 not found.|
|Date Deposited:||20 Dec 2008|
|Last Modified:||05 Jul 2011 11:26|
|Link to this item (URI):||http://health-equity.lib.umd.edu/id/eprint/1256|
Actions (login required)